Vitamin D supplementation for patients with multiple sclerosis treated with interferon-beta: A randomized controlled trial assessing the effect on flu-like symptoms and immunomodulatory properties

BMC Neurology

Volumn 13, Issue , 2013, Pages

  Golan, Daniel ^a   Halhal, Basheer ^a,c   Glass Marmor, Lea ^a   Staun Ram, Elsebeth ^a   Rozenberg, Orit ^b   Lavi, Idit ^a   Dishon, Sara ^a   Barak, Mira ^b   Ish Shalom, Sophia ^c   Miller, Ariel ^a,c  

^a CARMEL MEDICAL CENTER   (Israel)

^b CLALIT HEALTH SERVICES   (Israel)

^c TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Flu like symptoms; IL 17; Interferon ; Multiple sclerosis; PTH; Quality of life; Safety; Vitamin D

Indexed keywords

25 HYDROXYVITAMIN D; BETA INTERFERON; CALCIUM; COLECALCIFEROL; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 17; PARATHYROID HORMONE; CYTOKINE; IL17A PROTEIN, HUMAN;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG MEGADOSE; FEMALE; FLU LIKE SYNDROME; HUMAN; HYPERCALCEMIA; IMMUNOMODULATION; LOW DRUG DOSE; MALE; MULTIPLE SCLEROSIS; PROTEIN BLOOD LEVEL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RELAPSE; TELECONSULTATION; VITAMIN BLOOD LEVEL; VITAMIN SUPPLEMENTATION; AGED; BLOOD; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PATHOPHYSIOLOGY; TREATMENT OUTCOME;

ADULT; AGED; CHOLECALCIFEROL; CYTOKINES; DOUBLE-BLIND METHOD; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HUMANS; INTERFERON-BETA; INTERLEUKIN-17; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; TREATMENT OUTCOME;

EID: 84878895229     PISSN: None     EISSN: 14712377     Source Type: Journal    
DOI: 10.1186/1471-2377-13-60     Document Type: Article

References (46)

1. Munschauer FE, Kinkel RP. Managing side effects of interferon-beta in patients with relapsing-remitting multiple sclerosis. Clin Ther 1997, 19(5):883-893. 10.1016/S0149-2918(97)80042-2, 9385477.
2. O'Rourke KE, Hutchinson M. Stopping beta-interferon therapy in multiple sclerosis: an analysis of stopping patterns. Mult Scler 2005, 11(1):46-50. 10.1191/1352458505ms1131oa, 15732266.
3. Buttmann M, Merzyn C, Rieckmann P. Interferon-beta induces transient systemic IP-10/CXCL10 chemokine release in patients with multiple sclerosis. J Neuroimmunol 2004, 156(1-2):195-203.
4. Buttmann M, Merzyn C, Hofstetter HH, Rieckmann P. TRAIL, CXCL10 and CCL2 plasma levels during long-term Interferon-beta treatment of patients with multiple sclerosis correlate with flu-like adverse effects but do not predict therapeutic response. J Neuroimmunol 2007, 190(1-2):170-176.
5. Turk S, Akbulut M, Yildiz A, Gurbilek M, Gonen S, Tombul Z, Yeksan M. Comparative effect of oral pulse and intravenous calcitriol treatment in hemodialysis patients: the effect on serum IL-1 and IL-6 levels and bone mineral density. Nephron 2002, 90(2):188-194. 10.1159/000049041, 11818704.
6. Müller K, Haahr PM, Diamant M, Rieneck K, Kharazmi A, Bendtzen K. 1,25-Dihydroxyvitamin D3 inhibits cytokine production by human blood monocytes at the post-transcriptional level. Cytokine 1992, 4(6):506-512. 10.1016/1043-4666(92)90012-G, 1337987.
7. Zhang X, Li P, Bao J, Nicosia SV, Wang H, Enkemann SA, Bai W. Suppression of death receptor-mediated apoptosis by 1,25-dihydroxyvitamin D3 revealed by microarray analysis. J Biol Chem 2005, 280(42):35458-35468. 10.1074/jbc.M506648200, 3249976, 16093247.
8. Stewart N, Simpson S, van der Mei I, Ponsonby A-L, Blizzard L, Dwyer T, Pittas F, Eyles D, Ko P, Taylor BV. Interferon-β and serum 25-hydroxyvitamin D interact to modulate relapse risk in MS. Neurology 2012, 79(3):254-260. 10.1212/WNL.0b013e31825fded9, 22700816.
9. Løken-Amsrud KI, Holmøy T, Bakke SJ, Beiske AG, Bjerve KS, Bjørnarå BT, Hovdal H, Lilleås F, Midgard R, Pedersen T, Benth JS, Sandvik L, Torkildsen O, Wergeland S, Myhr KM. Vitamin D and disease activity in multiple sclerosis before and during interferon β treatment. Neurology 2012, 79(3):267-273. 10.1212/WNL.0b013e31825fdf01, 22700809.
10. Golan D, Staun-Ram E, Glass-Marmor L, Lavi I, Rosenberg O, Dishon S, Barak M, Ish-Shalom S, Miller A. The influence of vitamin D supplementation on melatonin status in patients with multiple sclerosis. Brain Behav Immun 2013, In press. [http://dx.doi.org/10.1016/j.bbi.2013.04.010].
11. Soilu-Hänninen M, Åivo J, Lindström BM, Elovaara I, Sumelahti ML, Färkkilä M, Tienari P, Atula S, Sarasoja T, Herrala L, et al. A randomised, double blind, placebo controlled trial with vitamin D3 as an add on treatment to interferon beta-1b in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry 2012, 83(5):565-571. 10.1136/jnnp-2011-301876, 22362918.
12. Weber MS, Hemmer B. Cooperation of B Cells and T Cells in the pathogenesis of Multiple Sclerosis. Molecular Basis of Multiple Sclerosis. Volume 51 2010, 115-126. Heidelberg: Springer, Martin R, Lutterotti A.
13. Kiedorf K, Wang Y, Neumann H. Immune-Mediated CNS damage. Molecular Basis of Multiple Sclerosis. Volume 51 2010, 173-196. Heidelberg: Springer, Martin R, Lutterotti A.
14. Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, Fujihara K, Havrdova E, Hutchinson M, Kappos L, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011, 69(2):292-302. 10.1002/ana.22366, 3084507, 21387374.
15. Bringhurst FR DM, Kronenberg HM. Hormones and disorders of mineral metabolism. Williams textbook of endocrinology 2008, 1217-1218. Philadelphia, PA: Saunders Elsevier, Kronenberg HM, Melmed S, Polonsky KS, Larsen PR, 11.
16. Buxton I. Pharmacokinetics and pharmacodynamics: the dynamics of drug absorption, distribution, action, and elimination. Goodman & Gilman's the pharmacological basis of therapeutics 2006, 1-41. New York: McGraw-Hill Medical Publishing Division, Brunton LL, 11.
17. Cella DF, Dineen K, Arnason B, Reder A, Webster KA, Karabatsos G, Chang C, Lloyd S, Steward J, Stefoski D. Validation of the functional assessment of multiple sclerosis quality of life instrument. Neurology 1996, 47(1):129-139. 10.1212/WNL.47.1.129, 8710066.
18. Ascherio A, Munger KL, Simon KC. Vitamin D and multiple sclerosis. Lancet Neurol 2010, 9(6):599-612. 10.1016/S1474-4422(10)70086-7, 20494325.
19. Knippenberg S, Bol Y, Damoiseaux J, Hupperts R, Smolders J. Vitamin D status in patients with MS is negatively correlated with depression, but not with fatigue. Acta Neurol Scand 2011, 124(3):171-175. 10.1111/j.1600-0404.2010.01447.x, 20880265.
20. Straube S, Andrew Moore R, Derry S, McQuay HJ. Vitamin D and chronic pain. Pain 2009, 141(1-2):10-13.
21. van Etten E, Gysemans C, Branisteanu DD, Verstuyf A, Bouillon R, Overbergh L, Mathieu C. Novel insights in the immune function of the vitamin D system: synergism with interferon-beta. J Steroid Biochem Mol Biol 2007, 103(3-5):546-551.
22. Institute of Medicine Dietary Reference Intakes for Calcium and Vitamin D 2011, Washington, DC: The National Academies Press, Institute of Medicine.
23. Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, Murad MH, Weaver CM. Evaluation, treatment, and prevention of vitamin D deficiency: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2011, 96:1911-1930. 10.1210/jc.2011-0385, 21646368.
24. Sanders KM, Stuart AL, Williamson EJ, Simpson JA, Kotowicz MA, Young D, Nicholson GC. Annual high-dose oral vitamin D and falls and fractures in older women: a randomized controlled trial. JAMA 2010, 303(18):1815-1822. 10.1001/jama.2010.594, 20460620.
25. Saliba W, Rennert HS, Kershenbaum A, Rennert G. Serum 25(OH)D concentrations in sunny Israel. Osteoporos Int 2012, 23(2):687-694. 10.1007/s00198-011-1597-y, 21416123.
26. Burton JM, Kimball S, Vieth R, Bar-Or A, Dosch HM, Cheung R, Gagne D, D'Souza C, Ursell M, O'Connor P. A phase I/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosis. Neurology 2010, 74(23):1852-1859. 10.1212/WNL.0b013e3181e1cec2, 2882221, 20427749.
27. Stein MS, Liu Y, Gray OM, Baker JE, Kolbe SC, Ditchfield MR, Egan GF, Mitchell PJ, Harrison LC, Butzkueven H, et al. A randomized trial of high-dose vitamin D2 in relapsing-remitting multiple sclerosis. Neurology 2011, 77(17):1611-1618. 10.1212/WNL.0b013e3182343274, 22025459.
28. Kampman MT, Steffensen LH, Mellgren SI, Jørgensen L. Effect of vitamin D3 supplementation on relapses, disease progression, and measures of function in persons with multiple sclerosis: exploratory outcomes from a double-blind randomised controlled trial. Mult Scler 2012, 18(8):1144-1151. 10.1177/1352458511434607, 22354743.
29. Korn TMM, Kuchroo VK. Immunological Basis for the Development of Tissue Inflammation and Organ-Specific Autoimmunity in Animal Models of Multiple Sclerosis. Molecular Basis of Multiple Sclerosis 2009, 51-57. Hamburg: Springer, Martin R, Lutterotti A, 1.
30. Tzartos JS, Friese MA, Craner MJ, Palace J, Newcombe J, Esiri MM, Fugger L. Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis. Am J Pathol 2008, 172(1):146-155. 10.2353/ajpath.2008.070690, 2189615, 18156204.
31. Chang SH, Chung Y, Dong C. Vitamin D suppresses Th17 cytokine production by inducing C/EBP homologous protein (CHOP) expression. J Biol Chem 2010, 285(50):38751-38755. 10.1074/jbc.C110.185777, 2998156, 20974859.
32. Joshi S, Pantalena LC, Liu XK, Gaffen SL, Liu H, Rohowsky-Kochan C, Ichiyama K, Yoshimura A, Steinman L, Christakos S, et al. 1,25-dihydroxyvitamin D(3) ameliorates Th17 autoimmunity via transcriptional modulation of interleukin-17A. Mol Cell Biol 2011, 31(17):3653-3669. 10.1128/MCB.05020-11, 3165548, 21746882.
33. Correale J, Ysrraelit MC, Gaitan MI. Immunomodulatory effects of Vitamin D in multiple sclerosis. Brain 2009, 132(Pt 5):1146-1160.
34. Hong J, Hutton GJ. Regulatory effects of interferon-beta on osteopontin and interleukin-17 expression in multiple sclerosis. J Interferon Cytokine Res 2010, 30(10):751-757. 10.1089/jir.2010.0082, 20874252.
35. Maes M, Stevens W, Scharpe S, Bosmans E, De Meyer F, D'Hondt P, Peeters D, Thompson P, Cosyns P, De Clerck L, et al. Seasonal variation in peripheral blood leukocyte subsets and in serum interleukin-6, and soluble interleukin-2 and -6 receptor concentrations in normal volunteers. Experientia 1994, 50(9):821-829. 10.1007/BF01956463, 7523180.
36. Killestein J, Rep MH, Meilof JF, Ader HJ, Uitdehaag BM, Barkhof F, van Lier RA, Polman CH. Seasonal variation in immune measurements and MRI markers of disease activity in MS. Neurology 2002, 58(7):1077-1080. 10.1212/WNL.58.7.1077, 11940696.
37. Bushnell SE, Zhao Z, Stebbins CC, Cadavid D, Buko AM, Whalley ET, Davis JA, Versage EM, Richert JR, Axtell RC, et al. Serum IL-17F does not predict poor response to IM IFNbeta-1a in relapsing-remitting MS. Neurology 2012, 79(6):531-537. 10.1212/WNL.0b013e318259e123, 22573631.
38. Kallaur AP, Oliveira SR, Colado Simao AN, de Almeida ER D, Kaminami Morimoto H, Lopes J, de Carvalho Jennings Pereira WL, Marques Andrade R, Muliterno Pelegrino L, Donizete Borelli S, et al. Cytokine profile in relapsing remitting multiple sclerosis patients and the association between progression and activity of the disease. Mol Med Rep 2013, 7(3):1010-1020.
39. Mahon BD, Gordon SA, Cruz J, Cosman F, Cantorna MT. Cytokine profile in patients with multiple sclerosis following vitamin D supplementation. J Neuroimmunol 2003, 134(1-2):128-132.
40. Vieth R, Kimball S, Hu A, Walfish PG. Randomized comparison of the effects of the vitamin D3 adequate intake versus 100 mcg (4000 IU) per day on biochemical responses and the wellbeing of patients. Nutr J 2004, 3:8. 10.1186/1475-2891-3-8, 506781, 15260882.
41. Geara AS, Castellanos MR, Bassil C, Schuller-Levis G, Park E, Smith M, Goldman M, Elsayegh S. Effects of parathyroid hormone on immune function. Clin Dev Immunol 2010, 2010:1-10.
42. Soilu-Hänninen M, Laaksonen M, Laitinen I, Erälinna J-P, Lilius E-M, Mononen I. A longitudinal study of serum 25-hydroxyvitamin D and intact parathyroid hormone levels indicate the importance of vitamin D and calcium homeostasis regulation in multiple sclerosis. J Neurol Neurosurg Psychiatry 2008, 79(2):152-157. 10.1136/jnnp.2006.105320, 17578859.
43. Smolders J, Menheere P, Thewissen M, Peelen E, Tervaert JW, Hupperts R, Damoiseaux J. Regulatory T cell function correlates with serum 25-hydroxyvitamin D, but not with 1,25-dihydroxyvitamin D, parathyroid hormone and calcium levels in patients with relapsing remitting multiple sclerosis. J Steroid Biochem Mol Biol 2010, 121(1-2):243-246.
44. Dobson R, Ramagopalan S, Giovannoni G. Bone health and multiple sclerosis. Mult Scler 2012, 18(11):1522-1528. 10.1177/1352458512453362, 22740489.
45. Munger KL, Levin LI, Hollis BW, Howard NS, Ascherio A. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA 2006, 296(23):2832-2838. 10.1001/jama.296.23.2832, 17179460.
46. Disanto G, Morahan JM, Ramagopalan SV. Multiple sclerosis: risk factors and their interactions. CNS Neurol Disord Drug Targets 2012, 11(5):545-555. 10.2174/187152712801661266, 22583442.